Partnership

Trimerbody formating services

The plug-and-play nature of LeadArtis technology enables the rapid creation of more powerful, more effective antibodies by simply incorporating the binding domains of pre-existing antibodies to the selected Trimerbody scaffold of our structure-based design. So far, all selected antigen binding domains incorporated into the Trimerbody scaffold have dramatically enhanced biological function compared to the parental antibody. A growing pipeline could be based on this approach to creating differentiated antibody drug candidates.
 
LeadArtis’s broad portfolio of Trimerbody formats are compatible with nearly any conventional antibody, single domain antibody or antibody mimetic. Trimerbody formatting provides enhanced performance in therapeutic antibody programs in preclinical and clinical development for the treatment of cancer, inflammatory and autoimmune disorders.
 
LeadArtis extends the use of the Trimerbody technology through licenses to interested partners. For instance, some partners advancing programs in clinical trials and numerous pre-clinical projects might consider Trimerbody as a backup program to reduce toxicity, extend circulatory half-life, improve stability and solubility, or add new binding domains (e.g. addition of tumor targeting) 

Overview

LeadArtis´s current business model includes the definition of an in-house pipeline and partnerships with other companies oriented to the combination of our technology with that of our collaborators.
 
Trimerbody® can be adapted to numerous protein configurations. There are multiple options to establish such relationships. Should you believe that our technology is of interest, we would be pleased to tell you more details and accommodate flexible avenues for collaboration schemes.  

Contact

Please direct partnering inquiries to:
 
Juan J. Pérez Villar PhD
jperezvillar@leadartis.com
+34 622243606

Start typing and press Enter to search